Program
tizanidine
Also written as “Tizanidine”, “Zanaflex Capsules” and “tizanidine 8 mg”.
Its studies are mostly in Muscle Spasticity · Cognitive Dysfunction · Melanoma · Multiple Sclerosis · Cerebral Palsy, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Teva Pharmaceutical Industries | 30 open or running | phase 2since Jul 27, 2006 | Feb 2, 2006 | none ahead |
| Acorda Therapeutics | 20 open or running | phase 2since Apr 22, 2013 | Jul 25, 2011 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Feb 8, 2010 | Feb 8, 2010 | none ahead |
| Elan Pharmaceuticals | 10 open or running | phase 3since Oct 8, 2002 | Oct 8, 2002 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 8, 2002First study: phase 3 study in Multiple SclerosisNew to Elan PharmaceuticalsElan Pharmaceuticals · NCT00047580 · 120 enrolled · United States
- Feb 2, 2006Teva Pharmaceutical Industries's first study: phase 1 study in Brain Injuries, TraumaticNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00287157 · 5 enrolled · Israel
- Jul 27, 2006Phase 2 study in Muscle SpasticityTeva Pharmaceutical Industries · NCT00358293 · 20 enrolled · Israel
- Apr 22, 2007Phase 2 study in Muscle SpasticityTeva Pharmaceutical Industries · NCT00464958 · 10 enrolled · Israel
- Feb 8, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01065987, NCT01146028
- Jul 25, 2011Acorda Therapeutics's first study: phase 1 study in Spasticity Due to Cerebral PalsyNew to Acorda TherapeuticsAcorda Therapeutics · NCT01405950 · 10 enrolled · United States
- Apr 22, 2013Phase 2 study in Muscle SpasticityAcorda Therapeutics · NCT01839279 · 136 enrolled · United States
TargetBeta
“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brimonidinerule | AbbVie | phase 4 | 54 |
| Dexmedetomidinerule | Pfizer | phase 4 | 46 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| Clonidinerule | pharmafina | phase 4 | 5 |
| lofexidinerule | uswm-llc-dba-us-worldmeds | phase 3 | 15 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT01839279Muscle Spasticity · United States | 2 | Completed | Acorda Therapeutics | Feb 2014 | 136 |
| NCT01405950Spasticity Due to Cerebral Palsy · United States | 1 | Terminated | Acorda Therapeutics | Mar 2012 | 10 |
| NCT01146028Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Sep 2001 | 42 |
| NCT01065987Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Sep 2001 | 24 |
| NCT00464958Muscle Spasticity · Israel | 2 | Terminated | Teva Pharmaceutical Industries | Dec 2008 | 10 |
| NCT00358293Muscle Spasticity · Israel | 2 | Completed | Teva Pharmaceutical Industries | 20 | |
| NCT00287157Brain Injuries, Traumatic · Israel | 1 | Completed | Teva Pharmaceutical Industries | 5 | |
| NCT00047580Multiple Sclerosis · United States | 3 | Completed | Elan Pharmaceuticals | 120 |
How it is read
Names in the registry
- “Tizanidine”, 4 entries
- “Zanaflex Capsules”, 4 entries
- “tizanidine 8 mg”, 1 entry
- “tizanidine 8mg”, 1 entry
- “tizanidine hydrochloride capsule”, 1 entry
Conditions, from the studies’ own filings
- Muscle Spasticity, 3 studies
- Cognitive Dysfunction, 1 study
- Melanoma, 1 study
- Multiple Sclerosis, 1 study
- Cerebral Palsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.